|
|
| (132 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32020915|t=2020. The Novel Coronavirus: A Bird s Eye View |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32112977|t=2020. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) |pdf=|usr=}}
| + | |
| − | {{tp|p=32125458|t=ä. COVID-19: a novel coronavirus and a novel challenge for critical care |pdf=|usr=}}
| + | |
| − | {{tp|p=32257431|t=2020. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Respiration mgmt]]''' |
| | | | |
| − | *'''[[Structure of covid19]]''' | + | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{tp|p=32361692|t=2020. How the COVID-19 Overcomes the Battle? An Approach to Virus Structure |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Target binding and uptake]]''' | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{tp|p=32344526|t=2020. COVID-19 and RAS: Unravelling an Unclear Relationship |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| | | | |
| − | *'''[[Cytopathic effects]]'''
| |
| | | | |
| | + | |
| | + | *'''[[Structure of covid19]]''' |
| | + | |
| | + | |
| | + | *'''[[Target binding and uptake]]''' |
| | + | *'''[[Cytopathic effects]]''' |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Innate sensing]]''' | | *'''[[Innate sensing]]''' |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32360285|t=ä. Type I IFN immunoprofiling in COVID-19 patients |pdf=|usr=}}
| |
| − | {{tp|p=32344056|t=ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination |pdf=|usr=}}
| |
| − | {{tp|p=32333914|t=ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32334118|t=ä. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32360286|t=2020. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32311489|t=ä. Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | ----
| + | *'''[[Pathobiology]]''' |
| | | | |
| | | | |
| − | *'''[[Early symptoms]]''' | + | *'''[[Disease Models]]''' |
| | | | |
| − | *'''[[Systemic disease, any manifestations]]'''
| |
| | | | |
| − | *'''[[Co-Infection]]''' | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| − | *'''[[Pulmonary embolism, coagulation]]'''
| |
| | | | |
| | | | |
| − | *'''[[Hematology]]''' | + | *'''[[Early symptoms]]''' |
| | | | |
| − | *'''[[Microvascular]]''' | + | *'''[[Systemic disease, any manifestations]]''' |
| | | | |
| − | *'''[[Heart]]''' | + | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[Neurology, ophthalmology, orl]]'''
| |
| − | {{tp|p=32251791|t=2020. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 |pdf=|usr=}}
| |
| − | {{tp|p=32314322|t=ä. COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Pulmonary embolism, coagulation]]''' |
| | | | |
| − | *'''[[Dermatology]]'''
| |
| − | {{tp|p=32213305|t=2020. COVID-19 can present with a rash and be mistaken for dengue |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| | | | |
| − | *'''[[Kidney, urology]]'''
| |
| | | | |
| − | ----
| + | *'''[[Hematology]]''' |
| | | | |
| | | | |
| − | *'''[[Pathobiology]]'''
| |
| − | {{tp|p=32094336|t=2020. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Heart]]''' |
| | | | |
| − | *'''[[Disease Models]]'''
| |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]'''
| |
| − | ----
| |
| | | | |
| | + | *'''[[Neurology, ophthalmology, orl]]''' |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]'''
| |
| − | {{tp|p=32300101|t=2020. Saliva: potential diagnostic value and transmission of 2019-nCoV |pdf=|usr=}}
| |
| − | {{tp|p=32286019|t=2020. Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]''' | + | *'''[[Dermatology]]''' |
| − | {{tp|p=32091414|t=2020. Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features |pdf=|usr=}}
| + | |
| − | {{tp|p=32134800|t=2020. Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes |pdf=|usr=}}
| + | |
| − | {{tp|p=32118615|t=2020. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32304402|t=2020. The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics |pdf=|usr=}}
| + | |
| − | {{tp|p=32286021|t=2020. Imaging Findings in Four COVID-19 Patients |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | {{tp|p=32344326|t=2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Gastroenterology, hepatology]]''' |
| | | | |
| − | *'''[[Respiration mgmt]]''' | + | *'''[[Kidney, urology]]''' |
| − | {{tp|p=32251794|t=2020. Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?|pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| − | *'''[[Clinical guidelines and advice]]''' | + | *'''[[Risk and special populations]]''' |
| − | {{tp|p=32361701|t=2020. COVID-19 Rapid Guideline in Kidney Transplant Recipients |pdf=|usr=}}
| + | |
| − | {{tp|p=32378816|t=2020. Clinical Insights and Management Recommendations for COVID-19 Patients Hospitalized in Internal Medicine Departments: Recommendations by the Corona Department Heads in Israel |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Risk and special populations]]'''
| |
| − | {{tp|p=32355869|t=ä. The Dermatologist?s Perspective: Why is COVID-19 mortality lower in females than males?|pdf=|usr=}}
| |
| − | {{tp|p=32222883|t=ä. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection |pdf=|usr=}}
| |
| − | {{tp|p=32125452|t=ä. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China |pdf=|usr=}}
| |
| − | {{tp|p=32297089|t=ä. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients |pdf=|usr=}}
| |
| − | {{tp|p=32361701|t=2020. COVID-19 Rapid Guideline in Kidney Transplant Recipients |pdf=|usr=}}
| |
| − | {{tp|p=32349772|t=2020. Novel Coronavirus disease (COVID-19) in newborns and infants: what we know so far |pdf=|usr=}}
| |
| − | {{tp|p=32333915|t=ä. Association of Respiratory Allergy, Asthma and Expression of the SARS-CoV-2 Receptor, ACE2 |pdf=|usr=}}
| |
| − | {{tp|p=C7152876|t=ä. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan |pdf=|usr=}}
| |
| − | {{tp|p=32371047|t=ä. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32344190|t=ä. Debate on Drugs That May Aggravate COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32224277|t=2020. COVID-19 and immunomodulator/immunosuppressant use in dermatology |pdf=|usr=}}
| |
| − | {{tp|p=32199889|t=2020. Should biologics for psoriasis be interrupted in the era of COVID-19?|pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| | | | |
| | | | |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32269194|t=2020. Pneumonia Without Respiratory Symptoms |pdf=|usr=}}
| |
| − | {{tp|p=32361703|t=2020. Newly Diagnosed Glomerulonephritis During COVID-19 Infection Undergoing Immunosuppression Therapy, a Case Report |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| | *'''[[Case series]]''' | | *'''[[Case series]]''' |
| − | {{tp|p=32378815|t=2020. Clinical Characterization of 162 COVID-19 patients in Israel: Preliminary Report from a Large Tertiary Center |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32368489|t=2020. The pathogenesis and alternative treatment of SARS-CoV2 |pdf=|usr=}}
| |
| − | {{tp|p=32289016|t=2020. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines |pdf=|usr=}}
| |
| − | {{tp|p=32125455|t=ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target |pdf=|usr=}}
| |
| − | {{tp|p=32347443|t=ä. Camostat mesilate therapy for COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32333086|t=ä. Remdesivir bei Patienten mit schwerer COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32378817|t=2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients |pdf=|usr=}}
| |
| − | *[https://www.nature.com/articles/d41573-020-00073-5 Nature: The COVID-19 vaccine development landscape]
| |
| | | | |
| − | ----
| + | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| | *'''[[Biophysics of aerosols]]''' | | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Other routes of infection]]'''
| |
| − | {{tp|p=32335340|t=ä. Potential Fecal Transmission of SARS-CoV-2: Current Evidence and Implications for Public Health |pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]''' | + | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32200109|t=2020. SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge |pdf=|usr=}}
| + | |
| − | {{tp|p=32251796|t=ä. The enlightenment from two cases of asymptomatic infection with SARS-CoV-2: is it safe after 14 days of isolation?|pdf=|usr=}}
| + | |
| − | {{tp|p=32147538|t=2020. Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report |pdf=|usr=}}
| + | |
| | | | |
| − |
| |
| − | *'''[[Passive protective equipment]]'''
| |
| − | {{tp|p=32325718|t=2020. Personal Safety during the COVID-19 Pandemic: Realities and Perspectives of Healthcare Workers in Latin America |pdf=|usr=}}
| |
| − | {{tp|p=32334119|t=ä. Addressing the corona virus outbreak: will a novel filtered eye mask help?|pdf=|usr=}}
| |
| − | {{tp|p=32203757|t=2020. Policies on the use of respiratory protection for hospital health workers to protect from coronavirus disease (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32265088|t=ä. Custom-made 3D-printed face masks in case of pandemic crisis situations with a lack of commercially available FFP2/3 masks |pdf=|usr=}}
| |
| − | {{tp|p=32171808|t=2020. Skin damage among health care workers managing coronavirus disease-2019 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32289019|t=2020. The COVID-19 pandemic: The ?black swan? for mental health care and a turning point for e-health |pdf=|usr=}}
| |
| − | {{tp|p=32339137|t=2020. Mental health and a novel coronavirus (2019-nCoV) in China |pdf=|usr=}}
| |
| − | {{tp|p=32243877|t=2020. Running a virtual allergy division and training program in the time of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32317114|t=ä. An academic allergy unit during COVID-19 pandemic in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32224232|t=ä. COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic |pdf=|usr=}}
| |
| − | {{tp|p=32220575|t=ä. Telemedicine in the Era of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32278865|t=ä. Health-Related Quality of Life in Common Variable Immunodeficiency Italian Patients Switched to Remote Assistance During the COVID-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32315792|t=ä. Acute At Home Management of Anaphylaxis During The Covid-19 Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32304834|t=ä. Risk Communication During COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32224276|t=2020. Ethical outpatient dermatology care during the coronavirus (COVID-19) pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32213307|t=2020. Dermatology practices as vectors for COVID-19 transmission: A call for immediate cessation of nonemergent dermatology visits |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32259628|t=ä. Clinician Wellness During the COVID-19 Pandemic: Extraordinary Times and Unusual Challenges for the Allergist/Immunologist |pdf=|usr=}}
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32360185|t=ä. Exercise and Fitness in the age of social distancing during the COVID-19 Pandemic |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − | {{tp|p=32325710|t=2020. The COVID-19 Outbreak and Affected Countries Stock Markets Response |pdf=|usr=}}
| |
| − | {{tp|p=32305533|t=ä. The Socio-Economic Implications of the Coronavirus and COVID-19 Pandemic: A Review |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 225: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32212099|t=ä. COVID-19 may transmit through aerosol |pdf=|usr=}}
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | | | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32225178|t=2020. The Impact of COVID-19 on Italy: A Lesson for the Future |pdf=|usr=}}
| |
| − | {{tp|p=32218558|t=2020. Preparedness and Lessons Learned from the Novel Coronavirus Disease |pdf=|usr=}}
| |
| − | {{tp|p=32271914|t=ä. The hearth of mathematical and statistical modelling during the Coronavirus pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32123989|t=ä. The novel coronavirus (SARS-CoV-2) infections in China: prevention, control and challenges |pdf=|usr=}}
| |
| − | {{tp|p=32219674|t=ä. Application of personal-oriented digital technology in preventing transmission of COVID-19, China |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Failure of politics and public health guidance]]''' | + | |
| | + | |
| | + | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − | {{tp|p=32316647|t=2020. Using Social Media to Mine and Analyze Public Opinion Related to COVID-19 in China |pdf=|usr=}}
| + | |
| − | *[https://www.businessinsider.com/nearly-half-of-reopen-america-twitter-accounts-are-bots-report-2020-5?utmSource=twitter&utmContent=referral&utmTerm=topbar&referrer=twitter twitter botwar]
| + | |
| | | | |
| | | | |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| − | {{tp|p=32142979|t=2020. Li Wenliang, a face to the frontline healthcare worker The first doctor to notify the emergence of the SARS-CoV-2, (COVID-19), outbreak |pdf=|usr=}}
| |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − |
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32175070|t=2020. Positive Screening for Wuhan Novel Coronavirus Infection at International Airport: What s the Final Diagnosis for Positive Cases |pdf=|usr=}}
| + | |
| − | {{tp|p=32372270|t=ä. Three further ways that the COVID-19 pandemic will affect health outcomes |pdf=|usr=}}
| + | |
| − | {{tp|p=32307030|t=ä. The fight against COVID-19: a report from the Italian trenches |pdf=|usr=}}
| + | |
| − | {{tp|p=32210483|t=2020. The Battle Against COVID-19: Where Do We Stand Now?|pdf=|usr=}}
| + | |
| − | {{tp|p=32344058|t=ä. COVID-19 diagnostic process in mainland China: the math beyond pneumonia |pdf=|usr=}}
| + | |
| − | {{tp|p=32348792|t=ä. Will environmental impacts of social distancing due to the pandemic caused by SARS-CoV-2 decrease allergic disease?|pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | + | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| | | | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
